{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:32Z","timestamp":1792839692392,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    B\u2010cell non\u2010Hodgkin lymphoma (NHL) in one of the most serious extrahepatic manifestations of chronic hepatitis C virus (HCV) infection. No prospective studies have been conducted in the United States (US) on the impact of direct\u2010acting antivirals (DAAs) in HCV\u2010infected patients with indolent B\u2010cell NHL not requiring chemotherapy. In this prospective study, we evaluated the general characteristics of US patients with HCV\u2010associated indolent B\u2010cell NHL and the oncologic impact of only DAA treatment without systemic cancer therapy in those patients. We enrolled patients seen at our center during 2014\u20132021; we analyzed only chemotherapy\u2010na\u00efve patients treated with DAAs. Patients who required immediate conventional treatment for lymphoma were excluded from the study. The primary endpoints were sustained virologic response at 12\u00a0weeks (SVR12) and lymphoproliferative disease response, classified as complete response, partial response, stable disease, or progressive disease. The secondary endpoints were overall response rate (ORR) of NHL, duration of response (DOR), overall survival (OS), and progression\u2010free survival (PFS). Nine patients met the study criteria and were analyzed. Most patients were male (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a06), White (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a06), younger than 65\u00a0years (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a06), and non\u2010cirrhotic (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a08); had HCV genotype 1 (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a05); and had been infected for more than 30\u00a0years (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a07). All patients achieved SVR12. Six patients (67%) had complete response, and 3 (33%) had progressive disease. The ORR was 67%. The median DOR was 51\u00a0months (range 16\u201381\u00a0months). The 5\u2010year DOR, OS, and PFS rates were 100%, 83%, and 67%, respectively. HCV\u2010associated NHL is a late extrahepatic complication of HCV. Infected patients with indolent NHL have an excellent virologic responses to DAAs and most of them experienced a favorable oncologic response after HCV eradication without chemotherapy.\n                  <\/jats:p>","DOI":"10.1002\/hon.70044","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T06:58:57Z","timestamp":1739084337000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Direct\u2010Acting Antivirals Induce Lymphoproliferative Disease Response in HCV\u2010Infected Patients With Indolent B\u2010Cell Non\u2010Hodgkin\u2019s Lymphoma: A Prospective Observational Study"],"prefix":"10.1002","volume":"43","author":[{"given":"Monica","family":"George","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalis","family":"Mustafayev","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-604X","authenticated-orcid":false,"given":"Harrys A.","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center  Houston Texas USA"},{"name":"Department of Gastroenterology Hepatology and Nutrition The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2033539"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29845"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.09.031"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201012\u2010618652"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1513288"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100687\u20102"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201005\u2010714667"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00668"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx635"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu166"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010643569"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.3692"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000444"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0037"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12518"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26167"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.03.002"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.08.012"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.16"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:54:17Z","timestamp":1755503657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/hon.70044"],"URL":"https:\/\/doi.org\/10.1002\/hon.70044","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.70044\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70044\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70044\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70044\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70044\/v2\/response1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"2024-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70044"}}